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Essentials
• Obesity is a potential risk factor for development of thrombotic thrombocytopenic purpura (TTP).
• Obese ADAMTS-13-deficient mice were triggered with von Willebrand factor (VWF).
• Depletion of hepatic and splenic macrophages protects against thrombocytopenia in this model.
• VWF enhances phagocytosis of platelets by macrophages, dose-dependently.
Summary. Background: Thrombotic thrombocytopenic purpura (TTP) is caused by the absence of ADAMTS-13 activity. Thrombocytopenia is presumably related to the formation of microthrombi rich in von Willebrand factor (VWF) and platelets. Obesity may be a risk factor for TTP; it is associated with abundance of macrophages that may phagocytose platelets. Objectives: To evaluate the role of obesity and ADAMTS-13 deficiency in TTP, and to establish whether macrophages contribute to thrombocytopenia. Methods: Lean or obese ADAMTS-13-deficient (Adamts-13 À/À ) and wild-type (WT) mice were injected with 250 U kg À1 of recombinant human VWF (rVWF), and TTP characteristics were evaluated 24 h later. In separate experiments, macrophages were depleted in the liver and spleen of lean and obese WT or Adamts-13 À/À mice by injection of clodronate-liposomes, 48 h before injection of rVWF. Results: Obese Adamts-13
mice had a lower platelet count than their lean counterparts, suggesting that they might be more susceptible to TTP development. Lean Adamts-13 À/À mice triggered with a threshold dose of rVWF did not develop TTP, whereas typical TTP symptoms developed in obese Adamts-13 À/À mice, including severe thrombocytopenia and higher lactate dehydrogenase (LDH) levels. Removal of hepatic and splenic macrophages by clodronate injection in obese Adamts-13 À/À mice before treatment with
Introduction
Thrombotic thrombocytopenic purpura (TTP) is a lifethreatening disease caused by absence of ADAMTS-13 (A Disintegrin And Metalloproteinase with ThromboSpondin 1 motif, member 13) activity, which cleaves prothrombotic ultra-large von Willebrand factor multimers (UL-VWF). TTP is characterized by formation of platelet-rich microthrombi in capillaries and arterioles that can lead to organ failure and death. Other symptoms are severe thrombocytopenia, microangiopathic hemolytic anemia, fever and neurological dysfunctions [1] . Pregnancy, alcohol abuse, infections and surgery are common risk factors for TTP development [2] . Also, in most animal models, triggers are needed to induce TTP [3] . Indeed, Adamts-13 À/À mice do not spontaneously develop TTP, but it can be triggered by injection of a high dose of recombinant VWF (rVWF) [4] or of Shiga toxin [5] . Furthermore, baboons injected with an inhibitory anti-ADAMTS-13 monoclonal antibody (without additional trigger) show signs of early stages of TTP (severe thrombocytopenia, hemolytic anemia, increased lactate dehydrogenase (LDH) levels and VWF-rich microthrombi), but not of late stage TTP (organ failure and death) [6] . We previously observed higher levels of ADAMTS-13 antigen and activity in obese compared with lean mice [7] . This is in agreement with higher expression levels of ADAMTS-13 in livers of obese mice [8] . Therefore, obesity would not be expected to be a risk factor for TTP, as it is associated with higher levels of the VWF-cleaving proteinase ADAMTS-13. Moreover, ADAMTS-13 has anti-inflammatory properties [9] , whereas obesity is a state of low-grade chronic inflammation [10] . Recent emerging data, however, suggest that obesity may be a trigger for acute TTP in man. Thus, in patients with body mass index (BMI) > 30 kg m À ² obesity was identified as a potential inducer of TTP with an odds ratio of 7.6 [11] , and in the Oklahoma Registry of TTP patients more than 25% were morbidly obese (BMI > 40 kg m À ²) [12] . Furthermore, a positive correlation was established between ADAMTS-13 levels and BMI in humans [13] . In the present study, we have evaluated the combined effect of obesity and ADAMTS-13 deficiency in mice on the development of an experimentally induced TTP phenotype. It was also reported that macrophages play a role in thrombocytopenia associated with von Willebrand disease [14] . In TTP patients, it is assumed that severe thrombocytopenia is a consequence of the formation of microthrombi that are VWF and platelet rich [15] . Because macrophages are abundant in the obese state and can phagocytose and clear platelets from the circulation [16] , we have investigated whether platelet clearance by macrophages in the liver and spleen could contribute to TTPrelated thrombocytopenia.
Materials and methods

Animal models
Male Adamts-13 À/À and wild-type (WT) littermate mice (genetic background: C57Bl6/J x 129X1/Sv x CASA/RK) [5] were kept on a standard-fat diet (SFD, lean) (KM-04-k12, Muracon, Carfil, Oud-Turnhout, Belgium; 13% kcal as fat, caloric value 10.9 kJ g
À1
) or a high-fat diet (HFD, obese) (E15721-34, Ssniff, Soest, Germany; 42% kcal as fat, caloric value 22 kJ g À1 ) (n = 20 WT and Adamts-13 ) of rVWF. Blood was taken via the retro-orbital plexus under anesthesia with isoflurane at several time points (24, 48, 72, 96 and 120 h) after injection to measure the platelet count.
Analysis
Murine ADAMTS-13 and VWF levels in plasma were determined by ELISA as described previously [7, 17] . Pooled plasma of WT mice was used as reference; this contains 4 lg mL À1 of murine VWF, as determined by ELISA calibrated with purified murine VWF. Paraffin sections (4 lm) for histology were prepared from isolated livers. Antigens were unmasked using antigen retrieval solution (Dako, Leuven, Belgium). To remove endogenous peroxidase activity, sections were incubated in 0.3% hydrogen peroxide in PBS. Macrophages or platelets were stained overnight with a F4/80 (Serotec, Raleigh, NC, USA) (1/5000) or GP1ba (#M042-0, Emfret, Eibelstadt, Germany) (1/500) antibody, respectively. Afterwards, a biotin labeled rabbit-anti-rat antibody (Life Technologies, Carlsbad, CA, USA) was used as a secondary antibody (1/5000 or 1/300 dilution, respectively). F4/80 staining was followed by signal amplification with the tyramide signal amplification biotin system (Perkin Elmer, Waltham, MA, USA) and visualization with a streptavidinenzyme conjugate, followed by 3,3'-diaminobenzidine (DAB). GPIba was visualized by the ABC-kit (Vector Laboratories, Burlisgame, CA, USA) and DAB. Data are quantitatively expressed as percentage staining of section area. Analyses were performed with a Zeiss Axioplan 2 microscope and the AxioVision release 4.8 software (Carl Zeiss). Gene expression of F4/80, IL-1b, MRC-1 and TNF-a in liver tissue and F4/80, IL-1b, CD68 and TNF-a in spleen tissue was analyzed by qPCR as described previously [7] . Lactate dehydrogenase (LDH) activity levels were measured in plasma by the Lactate Dehydrogenase Activity Assay according to the manufacturer's protocol (BioVision Incorporated, Milpitas, CA, USA).
Platelet isolation and labeling
For the in vitro study, lean WT mice were anesthetized with pentobarbital and blood was obtained by cardiac puncture, diluted (6/1) in ACD buffer (ACD: 93 mM sodium citrate, 7 mM citric acid, 14 mM dextrose, pH 6.8 supplemented with apyrase (100 mU mL À1 )) (A6410, Sigma, Darmstadt, Germany); platelet-rich-plasma (PRP) was obtained by centrifugation at 1600 9 g for 30 s followed immediately by centrifugation at 115 9 g for 5 min. The PRP was diluted in ACD (1/3) and centrifuged at 950 9 g for 5 min, followed by resuspension of the platelet pellet in Tyrode's buffer (137 mM NaCl, 12 mM NaHCO 3 , 2 mM KCl, 0.34 mM Na 2 HPO4, 1 mM MgCl 2 , 2 mM CaCl 2 , 5.5 mM glucose and 5 mM HEPES [N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid], pH 7.4). Washed platelets were labeled with CMFDAGreen (10 lM for 30 min at 37°C) (Molecular Probes, Life Technologies). Afterwards 1 lM prostaglandin E1 (PGE1; Sigma Aldrich, Saint-Quentin, France) was added before centrifugation to suppress platelet activation during the removal step of non-incorporated dye.
For the in vivo study, obese WT mice were anesthetized with pentobarbital and blood was obtained by cardiac puncture in ACD-C buffer (124 mM tri-sodium citrate, 130 mM citric acid, 110 mM dextrose, pH6.5), and washed in wash buffer (140 mM NaCl, 5 mM KCl, 12 mM trisodium citrate, pH 6.5, supplemented with 100 mU mL À1 apyrase and 1 lM PGE1). PRP, obtained by centrifugation at 1600 9 g for 30 s followed immediately by centrifugation at 115 9 g for 5 min was supplemented by ACD (1/ 10), 100 mU mL À1 apyrase and 1 lM PGE1, and washed in wash buffer and centrifuged for 5 min at 950 9 g; platelets were finally diluted in Tyrode's buffer (10 mM HEPES, 140 mM NaCl, 3 mM KCl, 5 mM NaHCO 3 , 0.5 mM MgCl 2 and 10 mM glucose; pH 7.4). Washed platelets were labeled with CMTMR-Orange (10 lM for 30 min at 37°C) (Molecular Probes, Life Technologies) in Tyrode's buffer supplemented with 100 mU mL À1 apyrase and 1 lM PGE1. To remove non-incorporated dye, platelets were centrifuged for 5 min at 950 9 g.
In vitro platelet phagocytosis by macrophages
Four days after i.p. injection of 0.5 mL of 4% thioglycollate medium (T9032-500G; Sigma Aldrich), peritoneal macrophages were harvested in RPMI medium (Thermofisher Scientific, Gent, Belgium) and incubated with red blood cell (RBC) lysis buffer (eBioscience, San Diego, CA, USA) for 5 min. Cells were counted and seeded at a density of 500 9 10³ cells per well (3.8 cm²) in RPMI medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (PenStrep; Invitrogen, Paisly, UK) in 12-well microtiter plates (Costar, Corning Incorporated, New York, NY, USA). After attaching overnight, macrophages were washed with PBS to remove non-adherent cells and microtiter plates were incubated for 45 min in an atmosphere of 95% humidified air-5% CO 2 at 37°C with 5 lM Cell Tracker Orange CMTMR in DMEM/F12 (Thermofisher Scientific) supplemented with 10 mM L-glutamine (Thermofisher Scientific) and 1% PenStrep. Remaining dye was then removed by washing with PBS. CMFDA green-labeled washed murine platelets were added at a density of five platelets per macrophage, together with increasing doses of rVWF (0-15 U mL À1 ) and botrocetin (3 lg/mL/U rVWF; Sigma-Aldrich, Overijse, Belgium) to promote rVWF binding to platelets. Cells were incubated for 20 h in DMEM/F12 medium supplemented with 10 mM L-glutamine, 10% FBS and 1% PenStrep at 37°C, after which they were washed and fixed with 4% formaldehyde (Thermofisher Scientific) in PBS. Phagocytosis was analyzed and quantitated using a fluorescence Zeiss Axioplan 2 microscope (Carl Zeiss). For each condition, the total amount of macrophages, total amount of platelets, macrophages with ingested platelets (yellow) and total number of phagocytosed platelets were assessed.
In vivo platelet clearance/aggregation
Obese Adamts-13 À/À mice were injected with 10 lL g ) were injected via the tail vein into obese Adamts-13 À/À mice. The threshold dose of rVWF (250 U/ kg) was injected i.v. 1 h after injection of fluorescently labeled platelets. Mice were perfused by saline and killed by cervical translocation, before the liver and spleen were removed. Microaggregates/single platelets were qualitatively visualized using the fluorescence Zeiss Axioplan 2 microscope (Carl Zeiss).
Statistical analysis
Data are presented as mean AE standard error of the mean (SEM). Statistical significance between groups was analyzed with the non-parametric Mann-Whitney U-test or non-parametric Wilcoxon test. Analysis of the data was performed using Prism 6 (GraphPad Software Inc., San Diego, CA, USA). Values of P < 0.05 are considered statistically significant. the start and end of the diet for WT and Adamts-13 À/À mice. Data are mean AE SEM of 9-11 experiments with *P < 0.05, **P < 0.01 and ***P < 0.001;
Results
Obese Adamts-13 À/À mice do not spontaneously develop TTP After 15 weeks of HFD, both WT and Adamts-13
mice gained significantly more weight as compared with SFD feeding (Fig. 1A) , as observed previously [7] . This was associated with significantly enhanced ADAMTS-13 antigen levels after HFD feeding of WT mice, but with reduced levels after SFD feeding (Fig. 1B) . These differences may be a result of higher secretion of ADAMTS-13 on HFD as compared with SFD [7] . At the start of the diet, plasma VWF antigen levels were not different in the four groups (data not shown). After 15 weeks on HFD, VWF levels were significantly increased as compared with SFD feeding of both genotypes. On SFD, there was no significant difference between genotypes, whereas on HFD the VWF levels were lower for the Adamts-13 À/À mice than for the WT mice (Fig. 1C) . Plasma levels of lactate dehydrogenase (LDH) activity were significantly higher after HFD as compared with SFD feeding in Adamts-13 À/À mice, reflecting more red blood cell and organ damage, but were not affected by genotype (Fig. 1D ). Hemoglobin and hematocrit levels were not different between WT and Adamts-13 À/À mice on SFD or HFD (Table 1) . Obese (HFD) as compared with lean (SFD) mice of both genotypes displayed enhanced hepatic macrophage content, as determined by quantitative analysis of F4/80 staining (Fig. 1E) . Platelet count was comparable for WT and Adamts-13 À/À mice at the start of the diet. At the end of the diet, platelet counts were reduced for obese as compared with lean WT as well as Adamts-13 À/À mice (Fig. 1F) , suggesting that obesity may represent a risk factor for TTP. However, platelet counts for obese Adamts-13 À/À mice remained well above the level defined as thrombocytopenia (< 600 9 10³ lL À1 ).
rVWF induces TTP symptoms in obese Adamts-13
We determined a threshold dose of rVWF that significantly decreased platelet counts, but not below the level of thrombocytopenia. Therefore, decreasing doses of rVWF (2000 to 100 U kg À1 ) were injected into lean ) after 24 h in all mice, whereas with up to 250 U kg À1 only a moderate decrease of platelet count was observed. Therefore, a dose of 250 U kg À1 was selected as the threshold for further experiments, and platelet counts were measured 24 h after injection. Using this approach, injection of rVWF in obese WT or Adamts-13 À/À mice was associated with lower platelet counts as compared with lean mice (Fig. 2A) . In obese Adamts-13 À/ À mice, platelet count after injection dropped by 96%
(948 AE 46 9 10³ lL À1 at the end of the diet [ Fig. 1F ] vs.
35 AE 13 9 10³ lL À1 24 h after rVWF injection [ Fig. 2A] ), as compared with dropping by 29% for lean Adamts-13
vs. 803 AE 113 9 10³ lL À1 ). In contrast, lean and obese WT mice did not show marked thrombocytopenia after injection of a threshold dose of rVWF. Thus, obesity in an Adamts-13 À/À background promotes induction of severe thrombocytopenia upon injection with a threshold concentration of rVWF. In addition, plasma levels of LDH activity were significantly higher for obese as compared with lean 
Adamts-13
À/À mice or obese WT mice (Fig. 2B) , indicating more severe red blood cell and organ damage in obese Adamts-13 À/À mice 24 h after rVWF injection. Endogenous murine VWF antigen levels were higher in obese as compared with lean WT and Adamts-13 À/À mice, without marked effects of genotype (Fig. 2C) . Hemoglobin ( Fig. 2D) and hematocrit ( Fig. 2E ) levels were not different between obese and lean Adamts-13 À/À mice, thus not supporting hemolytic anemia or effects on hematopoiesis. Furthermore, analysis of schistocytes in blood smears (Fig. 2G) showed a significant increase after HFD as compared with SFD feeding for WT mice and a similar trend for Adamts-13 À/À mice; there was, however, no difference between WT and Adamts-13 À/À mice (Fig. 2F) .
Taken together, these data indicate that obesity could be a risk factor for development of TTP-related thrombocytopenia in genetically predisposed Adamts-13 À/À mice triggered by rVWF.
Hepatic macrophages contribute to severe thrombocytopenia HFD feeding was associated with enhanced hepatic macrophage content (Fig. 1E) , which may contribute to enhanced clearance of platelets and platelet-VWF complexes. Therefore, we have depleted macrophages in the liver (Kupffer cells) and spleen of lean and obese WT and Adamts-13 À/À mice by clodronate treatment before rVWF injection. Reduction of macrophage populations in all treated mice was confirmed by reduced F4/80 staining in the liver (Fig. 3A, I vs. II and Fig. 3B ) and by reduced expression of F4/80 in the liver and spleen as compared with PBS injection (Fig. 4A,B) . This was further supported by reduced expression of the macrophage markers IL-1b, MRC-1 and TNF-a in the liver (Fig. 4A) . Platelet counts at the end of the diet were not significantly affected by treatment with either clodronate or PBS (Fig. 5A) ). These differences were not observed for lean or obese WT mice. Thus, without macrophage depletion (PBS), platelet counts of obese Adamts-13 À/À mice were significantly lower than for obese WT mice (Fig. 5A) . GPIba staining was reduced in the livers of obese Adamts-13 À/À mice after macrophage depletion as compared with PBS-treated mice (Fig. 3A , III vs. IV and Fig. 3C ). F4/80 and GPIba staining in the liver was positively correlated in obese Adamts-13 À/À mice (P = 0.0002, r = 0.9), whereas GPIba positivity and platelet count in the blood (P = 0.008, r = À0.8), as well as F4/80 positivity and platelet count in the blood (P = 0.007, r = À0.8),
were negatively correlated in these mice. These correlations were not observed in lean Adamts-13 À/À or WT mice on either SFD or HFD. Furthermore, quantitation of platelets/platelet aggregates by GPIba staining revealed that these are markedly less prominent in liver and spleen of clodronate vs. PBS-treated mice (Fig. 6 A-C) . The incidence was also higher in liver as compared with spleen of PBS-treated mice. To confirm these findings, we isolated and fluorescently marked platelets from obese WT donor mice and injected these into obese Adamts-13 À/À mice before injection of rVWF. Twenty-four hours later, the liver and spleen were harvested to track the administered platelets. In mice with normal functioning macrophages, single platelets as well as platelet aggregates could be visualized, particularly in the liver (Fig. 6, DI) , whereas macrophage depletion strongly reduced platelet aggregate accumulations in the liver (Fig. 6, DII) . Treatment with clodronate caused a significant rise in endogenous VWF levels in lean as well as obese WT and Adamts-13 À/À mice as compared with PBS (Fig. 5B ).
Hemoglobin and hematocrit levels were comparable for all mice (data not shown). LDH activity was not markedly affected by diet only, but increased after depletion of the macrophages in all mice (Fig. 5C ). The incidence of schistocytes in fresh blood smears of Adamts-13 À/À mice tended to be (non-significantly) higher upon clodronate vs. PBS treatment for both lean (1.5 AE 0.4/500 RBC vs. 0.7 AE 0.1/500 RBC) and obese (0.7 AE 0.2/500 RBC vs. 0.4 AE 0.4/500 RBC) mice.
rVWF enhances platelet phagocytosis by macrophages
When fluorescently labeled platelets were added in vitro to fluorescently labeled macrophages in the presence of rVWF and botrocetin, phagocytosis of platelets was observed (Fig. 7A) . The total number of macrophages that phagocytosed platelets was not affected by rVWF (Fig. 7B) , whereas the proportion of phagocytosed platelets increased with rising concentrations of rVWF (Fig. 7C, D) .
Discussion
TTP is an extremely rare, but life-threatening disease caused by the absence of ADAMTS-13 activity, the VWF cleaving proteinase, whereby microthrombi are formed in the microcirculation, causing tissue damage and ultimately death [1, 2] . TTP patients may have a genetic predisposition, but an additional triggering factor is needed to evoke an acute TTP episode. Known triggers include pregnancy, HIV infection and alcohol abuse. However, in many cases the trigger remains unknown, and therefore the exact etiology of TTP remains unclear [18] . Interestingly, obesity, which is a state of chronic inflammation, was found to be associated with higher ADAMTS-13 levels in mice and men [8, 13] . Nonetheless, obesity was suggested to be a possible risk factor for TTP [11] . Although apparently contradictory, there are indications that obesity is indeed a risk factor for TTP. Thus, in the Oklahoma TTP cohort study, morbid obesity had a significantly higher prevalence in TTP patients [12] , and ADAMTS-13 levels were lower in obese TTP patients as compared with patients with a healthy BMI [19, 20] . In contrast, in 21% of obese patients undergoing bariatric surgery, non-inhibitory ADAMTS-13 autoantibodies were detected, whereas ADAMTS-13 antigen and activity levels were comparable to lean subjects [21] . Weight loss after bariatric surgery was associated with a reduction of anti-ADAMTS-13 autoantibodies [22] . We previously reported that obese Adamts-13 À/À mice had a slightly lower platelet count and more hepatic microthrombi than obese WT or lean Adamts-13 À/À mice [23] . However, these mice did not suffer from severe thrombocytopenia and did not show marked organ damage or blood schistocytes, and thus did not represent a useful model of TTP.
In this study, we show that obesity is indeed a risk factor for TTP in Adamts-13 À/À mice, as injection of a threshold dose of rVWF (250 U kg
À1
) resulted in severe thrombocytopenia and organ damage. Thus, when both risk factors, obesity and deficiency of ADAMTS-13, are present, mice are more susceptible to development of TTP-related thrombocytopenia upon triggering by rVWF.
The human body produces and removes up to 10 11 platelets daily in order to maintain a normal steady-state platelet count. Multiple mechanisms may contribute to platelet production and clearance (reviewed in [24] ). It was shown that macrophages play a crucial role in clearance of platelets and platelet-VWF complexes [25, 26] . Indeed, increased clearance of platelet-VWF complexes by macrophages in liver and spleen contributes to the thrombocytopenia associated with von Willebrand disease type 2B, which is characterized by enhanced affinity of VWF for platelets [14] .
Because of the inflammatory state, obesity is especially associated with an increase in pro-inflammatory M1 macrophages in the adipose tissue [27] and in the liver [28] . Thus, whereas obesity is associated with enhanced ADAMTS-13 levels in mice [7] , it also causes more abundant macrophage populations. The expected protective effect of enhanced ADAMTS-13 levels on TTP development by reducing microthrombi formation may therefore be blunted by higher macrophage content, which may lead to enhanced platelet clearance. In order to further investigate a potential causative relation between enhanced macrophage content and reduced platelet counts in TTP, we have depleted hepatic and splenic macrophages by clodronate treatment. Clodronate treatment by itself had no effect on platelet counts in either lean or obese WT or Adamts-13 À/À mice. Reduced macrophage populations (clodronate) in both lean and obese Adamts-13 À/À mice were indeed associated with higher platelet counts after triggering with rVWF as compared with PBS treatment; these effects were more pronounced in the obese mice. A causal relationship between both observations for obese Adamts-13 À/À mice is further suggested by (i) a negative correlation between hepatic macrophage content and blood platelet counts; (ii) a positive correlation between hepatic macrophage populations and hepatic platelet content (GPIba staining); (iii) a negative correlation between hepatic and blood platelet content; and (iv) a negative correlation between splenic macrophage content and blood platelet counts. Taken together, these observations indicate that higher platelet clearance in control (PBS treated) obese Adamts-13
mice is mediated by macrophages. These correlations were not observed in lean Adamts-13 À/À mice, nor in WT mice; probably, cleavage of UL-VWF by ADAMTS-13 in WT mice reduces complex formation. Therefore, deficiency of ADAMTS-13 and obesity appear combined risk factors for severe thrombocytopenia as seen in TTP. Endogenous VWF levels were significantly elevated after clodronate treatment of lean and obese mice, possibly reflecting reduced clearance after macrophage depletion. By both in vitro and in vivo approaches, we showed that addition of rVWF causes enhanced phagocytosis of platelets by macrophages, probably as platelet-VWF complexes. Increasing doses of rVWF induced significantly more platelet phagocytosis by the same number of macrophages in vitro. Thus, in the presence of high doses of VWF, each macrophage phagocytizes a higher number of platelets. Furthermore, macrophage depletion in obese Adamts-13 À/À mice injected with VWF resulted in reduced accumulation of platelets/platelet aggregates in the liver and spleen (Fig. 6B,C) . The stimulating role of VWF in platelet phagocytosis by macrophages may also be relevant in other pathologies with associated thrombocytopenia. In such pathologies, treatments such as Caplacizumab that prevent platelet-VWF interactions [29] could be beneficial. Thus, in addition to microthrombi formation [30] , enhanced platelet clearance by upregulated macrophage populations may also contribute significantly to severe thrombocytopenia in obese subjects with TTP. Our data on platelet counts after macrophage depletion seem to indicate that macrophage-mediated phagocytosis is the predominant mechanism. Indeed, when this pathway is eliminated (clodronate), platelet counts after rVWF injection drop by only 33% or 11% for lean or obese Adamts-13 À/À mice, respectively, which would represent the contribution of microthrombosis to the observed platelet drop. This does not exclude the fact that microthrombi in critical small arterioles and capillaries can cause organ failure and death. Severe ischemic organ damage, particularly affecting the brain, heart and kidneys, is indeed a hallmark of the clinical manifestation of TTP [1] . We have, however, only occasionally detected microthrombi in other tissues such as brain or kidney, and the lack of quantitative data is a limitation of the present study. It should be kept in mind, however, that detection of VWFrich microthrombi in mouse models of TTP is very difficult, as reported previously by us [31] and by others [4] . Besides macrophages, neutrophils and monocytes may also contribute to platelet phagocytosis, as shown in patients with essential thrombocythemia or thrombocythemia vera [32] . In addition, Wang et al. [33] reported that administration of clodronate to mice drastically decreases circulating monocytes, without affecting any other leukocyte subtype. However, because monocyte levels are very low as compared with platelet counts (≤ 0.1%), it is unlikely that their elimination significantly contributes to the almost total preservation of platelets after clodronate and VWF injection in obese Adamts-13 À/ À mice (Fig. 5A ).
The animal model used in this study (a nutritionally induced obese Adamts-13 À/À mouse injected with 250 U kg À1 rVWF), albeit complex and time consuming, could be useful in studies to evaluate new pharmacological approaches. However, it still does not present all the characteristics of an ideal mouse model of TTP, such as high incidence of microthrombi, microangiopathic hemolytic anemia or neurological dysfunction, but it may be more suited to study thrombocytopenia and platelet clearance.
In conclusion, our data indicate that obesity is a risk factor for TTP development in genetically predisposed mice, and that hepatic (and splenic) macrophages play an active role in platelet clearance, leading to severe thrombocytopenia. It remains to be established whether obese individuals with low ADAMTS-13 activity are also at higher risk of TTP. Addendum L. Geys and E. Roose performed experimental work, analyzed and interpreted data, and participated in the writing process. C. Tersteeg performed experimental work, and analyzed and interpreted data. I. Scroyen, K. Vanhoorelbeke, M. F. Hoylaerts, and H. R. Lijnen designed the study, interpreted data, and participated in the writing process. H. Rottensteiner provided the rVWF. All authors approved the final version of the manuscript.
